Oncology Central

Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA


Aim: Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients. Materials & methods: Adults with newly diagnosed DLBCL and FL between 1 January 2008 and 31 October 2015 were identified in the Optum™ claims database. Healthcare costs and utilization were assessed from diagnosis date until end of follow-up. Results: A total of 1267 DLBCL- and 1595 FL-treated patients were identified. Mean per-patient, per-month cost during follow-up was US$11,890 for DLBCL and US$10,460 for FL. Healthcare costs and utilization decreased from year 1 to 2 following diagnosis, due to a decrease in chemotherapy services, inpatient admissions and other outpatient services. Conclusion: The economic burden of treated DLBCL and FL is considerable, especially in the first year following diagnosis.

Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative malignancies with a wide array of histologic subtypes. In 2017, an estimated 72,240 patients will be diagnosed with NHL in the United States (US), and NHL will cause an estimated 20,140 deaths [1]. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL, composing 30% of the annual NHL diagnoses [2]. The incidence of DLBCL increases with age, with a median age of 60 to 70 years at diagnosis [2,3]. Follicular lymphoma (FL) is the second most common subtype of NHL, accounting for approximately 15% to 20% of adult NHL [4,5]. The average age of individuals diagnosed with FL is about 60 years [4]. It has been estimated that approximately 20% of FL cases will transform into a faster growing DLBCL in 5 years and about 30% will do so in 10 years [6].

View full text





News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.